Login to Your Account

Sangamo Drops SB-509 After Phase IIb Fails; Other ZFPs OK

By Trista Morrison

Tuesday, October 4, 2011
Despite a Phase IIb failure in diabetic neuropathy that prompted Sangamo BioSciences Inc. to drop lead drug SB-509, analysts believe earlier-stage programs may give the firm's zinc finger protein (ZFP) platform a better chance to shine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription